Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 2838-2842, June 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolenko, V.
Right arrow Articles by Finke, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolenko, V.
Right arrow Articles by Finke, J. H.
[Cancer Research 59, 2838-2842, June 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Dead or Dying

Necrosis versus Apoptosis in Caspase-deficient Human RenalCell Carcinoma1

Vladimir Kolenko2,, 3, Robert G. Uzzo2, Ronald Bukowski, Neil H. Bander, Andrew C. Novick, Eric D. Hsi and James H. Finke

Departments of Immunology [V. K., R. G. U., R. B., J. H. F.], Urology [R. G. U., R. B., A. C. N., J. H. F.], Experimental Therapeutics [V. K., R. B., J. H. F.], and Pathology [E. D. H.], The Cleveland Clinic Foundation, Cleveland, Ohio 44195, and Department of Urology, Division of Urologic Oncology, The New York Hospital, Cornell University Medical Center, New York, New York 10021 [N. H. B.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
The antitumor effect of immuno- and chemotherapeutic agents is executed through stimulation of apoptotic programs in susceptible cells. Apoptosis induced in tumor cells requires activation of members of the caspase family of proteases. Deficient expression or activation of caspases may account in part for the failure of many current anticancer therapies. However, recent studies suggest that cell death can proceed in the absence of caspases. We investigated the susceptibility of human renal cell carcinoma (RCC) lines to two distinct modes of cell death, apoptosis and necrosis. RCC lines displayed almost complete resistance to apoptosis in response to the intracellular zinc chelator, N,N,N'N'-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN), which instead induced dramatic accumulation of nonapoptotic necrotic cells. Conversely, TPEN was a potent inducer of apoptosis in caspase-competent normal kidney cells (NK-72) and Jurkat T lymphocytes. Resistance to apoptosis in RCC lines correlated with almost complete loss of caspase-3 expression and variable down-regulation of caspase-7, caspase-8, and caspase-10. These data may explain the resistance of RCC to drugs inducing apoptosis and have important consequences for further attempts to manipulate tumor cell death.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
The cytotoxic effect of most immuno- and chemotherapeutic agents in vitro and in vivo depends on induction of apoptosis in susceptible tumor cells (1 , 2) . Apoptotic cell death is characterized by a series of unique events including phosphatidyl serine exposure, cell shrinkage, and condensation and fragmentation of chromatin (3) . There is strong evidence that sensitivity of various tumor types to current therapeutic methods critically depends on the expression and activation of multiple apoptosis-regulatory proteins. Down-regulation of the CD95 receptor/ligand system, deficient expression of caspase family members, or overexpression of antiapoptotic Bcl-2 protein have all been demonstrated in drug-resistant tumors (1 , 4 , 5) . Recently, substantial evidence has implicated mitochondria in apoptotic signaling pathways. Alterations in mitochondrial membrane structure and function and opening of mitochondrial permeability transition pores result in the release of cytochrome c into the cytosol, where it exerts its activating effect on caspases (6 , 7) . It is now clear that although inhibition of caspases can prevent nuclear apoptotic changes, it does not always prevent irreversible loss of cellular function. Convincing data provide direct evidence that upon changes in the mitochondrial permeability transition, the availability of members of the caspase family determine the choice between apoptotic and necrotic modes of cell death. Alterations of mitochondrial function induce apoptosis when downstream caspases can be activated; however, in cells with reduced expression or activation of effector caspases, mitochondrial dysfunction results in necrotic cell death (8) . In this work, we investigated the susceptibility of apoptosis-resistant RCC cells to necrotic modes of cell death. To investigate this, we used RCC lines in which expression of several caspase family members was found to be diminished with near complete loss of caspase-3 expression. We determined that these cell lines were almost completely resistant to apoptosis in response to the intracellular zinc chelator TPEN,4 although TPEN treatment resulted in a significant increase in the number of dead cells in culture. Using the pan caspase inhibitor Z-VAD.fmk, we could prevent apoptotic but not necrotic cell death in normal kidney (NK-72) and Jurkat cell lines. Therefore, apoptosis-resistant tumor cells may be eliminated through an alternative nonapoptotic pathway providing new targets for antitumor drug development.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Cell Lines and Culture Conditions.
Three established and well-characterized RCC lines (RCC-7, RCC-26B, and RCC-48; Ref. 9 ) were cultured in RPMI 1640 (Bio-Whittaker, Walkersville, MD) supplemented with 10% FCS (Hyclone, Logan, UT), L-glutamine (2 mM), gentamicin (50 mg/l), sodium pyruvate (1 mM), and nonessential amino acids (0.1 mM).

Antibodies and Reagents.
Antibodies used in Western blotting for caspase-3 and caspase-7 were obtained from Transduction Laboratories (Lexington, Kentucky). Antibody to caspase-8 was purchased from PharMingen (San Diego, CA). Antibody to caspase-10 was purchased from Alexis Corp. (San Diego, CA). Anti-actin antibody and TPEN were obtained from Sigma Chemical Co. (St. Louis, MO). Secondary horseradish peroxidase-conjugated sheep anti-mouse and donkey anti-rabbit antibodies were purchased from Amersham (Arlington Heights, IL). Broad spectrum caspase inhibitor Z-VAD.fmk was purchased from Calbiochem (San Diego, CA).

Measurement of Apoptosis and Necrosis.
DNA fragmentation was detected using The Phoenix Flow Systems, Inc. (San Diego, CA) APO-BRDU kit, according to the protocol provided with the kit. Briefly, cells were harvested, washed in PBS, resuspended in 1% paraformaldehyde for 15 min on ice, rinsed twice with ice-cold PBS, and fixed in 70% cold ethanol overnight. The fixed cells were washed twice in wash buffer, incubated with 50 µl of DNA labeling solution containing 10 µl terminal deoxynucleotidyl transferase reaction buffer, 0.75 µl of terminal deoxynucleotidyl transferase enzyme, 8 µl of Br-dUTP, and distilled H2O. Cells were rinsed prior to resuspending with fluorescein-PRB-1 antibody solution and analysis by flow cytometry in the presence of PI/RNase solution (0.5 ml). All analyses were performed on 3,000 to 10,000 events on the FACScan (Becton Dickinson) using an argon ion laser (Cyonics) with 15 mV of 488 nm excitation. Live gating of the forward and orthogonal scatter channels was used to exclude debris and to selectively acquire cell events. All values presented are based on percentage of cells as determined by light scatter. Individual fluorescence populations were determined through the use of acquisition and contouring/quadrant analysis software (Cell Quest, Becton Dickinson). Determination of dead cells was performed by FACS analysis of PI-stained nuclei as described previously (10) .

Apoptosis was also determined by conventional light microscopy for morphological changes. Specifically, cytospin samples were assessed for the cellular and nuclear changes characteristically associated with apoptotic cell death (cell shrinkage, chromatin condensation, and karyorrhexis).

Western Blot Analysis.
Cells were lysed as described previously (11) directly in buffer [50 mM Tris (pH 7.6), 150 mM NaCl, and 1% Triton X-100] containing protease inhibitors 5 µg/ml aprotinin, 2 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Samples were placed on ice for 20 min with occasional vortexing. Protein concentration was measured with a commercial kit (Bio-Rad, Richmond, CA). Equivalent amounts of proteins from whole-cell lysates (30 µg) were mixed with an equal volume of 2x Laemmli sample buffer, boiled and resolved by electrophoresis in 10% SDS-polyacrylamide gels (SDS-PAGE). The proteins were transferred from the gel to a nitrocellulose membrane using an electroblotting apparatus (Bio-Rad; 15 V, 3 mA/cm2 for 24 min). Membranes were incubated in blocking solution containing 5% nonfat dry milk, then in Tris-buffered saline overnight to inhibit nonspecific binding. The membranes were then incubated with specific antibody (1–3 µg/ml) for 2 h. After washing in Tris/0.1% Tween 20 for 30 min, membranes were incubated for another 30 min with horseradish peroxidase-conjugated secondary antibody. The membranes were then washed and developed with enhanced chemiluminescence (ECL Western Blotting kit; Amersham). For densitometry scanning, the developed X-Omat AR film was placed on a white light box by Fotodyn, and its image was captured by a high resolution CCD camera (Sierra Scientific). Image 1.57 was the program used to analyze the density of each band by graphically plotting the images and calculating the area under each peak.


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
Resistance to Apoptosis Correlates with Reduced Levels of Caspase Expression in Human Renal Cell Carcinoma.
Resistance of tumor cells to anticancer therapies may result from failure to activate apoptotic pathways in response to drug treatment. The antitumor effect of CTLs, an important effector of the cellular immune response, is executed primarily through the stimulation of the apoptotic program in target cells via the perforin/granzyme B or CD95/CD95 ligand pathways. Two basic apoptotic pathways have been described previously. The first involves the ligation of death receptors, resulting in the recruitment of adaptor proteins and caspase-8 and caspase-10, which then act to cleave and activate downstream caspases. In the second, cellular stress triggers mitochondrial release of cytochrome c, followed by activation of caspase-9. Both pathways converge on downstream effector caspases such as caspase-3 and caspase-7 (12 , 13) .

Human tumor cell lines derived from patients with RCC and other malignancies demonstrate resistance to apoptosis induced by soluble CD95-L or antibody to CD95, despite expressing CD95 (14 , 15) .5 Whereas drug-induced apoptosis in tumor cells is believed to be mediated in part by the CD95 receptor/ligand system (16) , tumor cell resistance to apoptotic signals mediated via death receptors correlates with resistance to apoptosis induced by anticancer drugs (15) . Furthermore, failure of tumors cells treated with cytotoxic agents to undergo apoptosis corresponds to total resistance to cell death in response to these agents. Treatment of caspase-deficient RCC tumor cell lines with conventional chemotherapeutic agents such as etoposide, paclitaxel, methotrexate, 5-fluorouracil, and gemcitabine failed to induce either necrosis or apoptosis (data not shown). Therefore, we investigated whether renal carcinoma cell lines resistant to CD95-triggered apoptosis were sensitive to apoptosis induced by the intracellular zinc chelator TPEN, which mediates programmed cell death independently of CD95 signaling events. This may be explained by the effects of zinc on mitochondrial function (17) .6 For these studies, we treated three RCC lines with TPEN using a human normal kidney cell line (NK-72) and Fas-sensitive Jurkat T lymphocytes as controls. As shown in Fig. 1Citation , after treatment with 25 µM TPEN for 24 h, all normal kidney cells and Jurkat T cells underwent apoptosis (97.9 and 99.9%, respectively) as assessed by TUNEL assay, whereas only a small number of tumor cells in each cell line tested had apoptotic DNA fragmentation. We next studied whether resistance to apoptosis in response to TPEN in tumor cells correlated with reduced levels of caspase expression. The expression of effector caspases (i.e., caspase-3 and caspase-7) as well as the expression of proximal members of caspase family (caspase-8 and caspase-10) was evaluated in RCC lines and control cells by Western blotting using specific anticaspase antibodies. Results of this study are shown in Fig. 2ACitation . In lysates from normal kidney cells (NK-72) and Jurkat T lymphocytes, the expression of all caspases evaluated was easily detected. In contrast, all RCC lines had significantly reduced levels of caspase-3 expression. Relative to levels of other caspases, expression in RCC lines was more variable, which was confirmed by densitometry scanning of Western blots (Fig. 2B)Citation . Reprobing the blots with an antiserum specific for actin confirmed loading equivalent amounts of proteins for all cell lines.



View larger version (23K):
[in this window]
[in a new window]
  		Fig. 1. Human renal carcinoma cells are resistant to apoptosis induced by TPEN. Three human RCC lines (RCC-7, RCC-26B, and RCC-48), human normal kidney cell line (NK-72), and Jurkat T lymphocytes were cultured in medium or in the presence of 25 µM TPEN for 24 h. DNA fragmentation was detected using TUNEL assay by flow cytometry. X axis, DNA content; Y axis, fluorescence intensity.

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 2. Reduced expression of caspases in human RCC lines. A, the expression of caspases in cell lysates from human RCC lines and control cells was detected by Western blotting analysis with anticaspase-3, anticaspase-7, anticaspase-8, and anticaspase-10 antibodies. Expression of actin was used to control equal gel loading. B, densitometry scan of immunoblot in A.

 
The data presented here demonstrate reduced but variable levels of caspase expression in RCC lines. The relative resistance to apoptosis in cases of RCC does not reflect simply diminished expression of any one particular caspase. However, because the activation of upstream initiator caspases is requisite for subsequent activation of downstream effector caspases, defects in any given member of the cascade predicts failure of subsequent downstream events.

TPEN Induces Necrosis in Apoptosis-resistant RCC Lines.
Under normal conditions, alterations in mitochondrial membrane structure and function trigger apoptosis. However, under conditions in which caspase expression or activation is precluded, mitochondrial dysfunction invariably leads to cell death, albeit by necrosis rather than apoptosis (8) . Here we show that RCC lines with deficient expression of certain members of the caspase family are almost completely resistant to apoptosis induced by TPEN. Morphological studies show that caspase-competent Jurkat T cells displayed nuclear fragmentation in response to treatment with TPEN, whereas nuclei of caspase-deficient renal carcinoma cells did not (Fig. 3A)Citation . However, although the nuclei of tumor cells were not fragmented, they remained condensed, and all cells detached from the plate after TPEN treatment with loss of cell viability (Fig. 3A)Citation . To further investigate whether these cell lines underwent nonapoptotic cell death, we used PI staining and FACS analysis. Cell membranes in viable cells are impermeable to PI. In contrast, only dead cells whose plasma membrane integrity has been disrupted, as is typical of necrotic cells, incorporate PI. The RCC samples described in Fig. 1Citation were next stained with PI and analyzed by flow cytometry. As demonstrated in Fig. 3BCitation , in contrast to the slight effect on the induction of apoptosis, TPEN treatment resulted in substantial accumulation of PI-positive cells in all RCC lines evaluated (RCC 7, 11.5% versus 49.3%; RCC 26B, 21.7% versus 64.3%; and RCC 48, 19.4% versus 50.5%). These data support the idea that cell death can proceed in cells with reduced levels of caspase expression or activation and raise the possibility that some pathways leading to cell death do not require the action of any caspases. In these instances, activation of specific caspases may be a byproduct of cell death rather then an indispensable component. An exception is cell death induced by ligation of death receptors, which is completely dependent on proper caspase level and function (18) . Our results indicate that although tumor cells with almost complete loss of caspase-3 expression and variable reduction in the expression of other caspases are almost completely resistant to apoptosis in response to TPEN, they are still capable of dying from necrosis. Additional experiments aimed at understanding the role that mitochondrial alterations play in mediating caspase-independent cell death may have important implications for the development of new therapeutic strategies to overcome the resistance of tumor cells to apoptosis induced by conventional therapies. Careful monitoring of both modes of cell death is critical for accurately evaluating the cytotoxic response of antitumor agents.



View larger version (74K):
[in this window]
[in a new window]
  		Fig. 3. A, morphological changes in cells treated with 25 µM of the intracellular zinc chelator TPEN for 24 h. Arrows, either fragmented (black) or condensed (white) nuclei. B, TPEN induces necrosis in apoptosis-resistant human RCC lines. Aliquots of RCC samples shown in Fig. 1Citation were used to measure the percentage of dead cells using FACS analysis of PI-stained nuclei. X axis, fluorescence intensity; Y axis, cell number.

 
TPEN Induces Necrosis in NK-72 Cells and Jurkat T Lymphocytes When the Apoptotic Mode of Death Is Prevented.
It now appears that cell death can proceed in the absence of caspase activation (19) . Whereas inhibition of caspases can prevent nuclear apoptotic changes, it will not de facto prevent irreversible loss of cellular function. Recent observations provide direct evidence that the ability of downstream or executioner caspases to become activated upon changes in mitochondrial permeability transition ultimately determine the choice between apoptotic and necrotic modes of cell death (8) .

To confirm the role of caspases in the modulation of cell death, we used the pan-caspase inhibitor Z-VAD.fmk to block activation of caspases in normal kidney cells and Jurkat T lymphocytes treated with TPEN. Z-VAD.fmk can effectively prevent the activation of caspase-3 like proteases and induction of nuclear apoptosis in response to various agents (20) . Here, NK-72 cells and Jurkat T lymphocytes were incubated in the presence or absence of 50 µM of Z-VAD.fmk for 30 min, followed by treatment with 25 µM TPEN for 24 h. The number of apoptotic and necrotic cells after treatment was assessed by TUNEL assay and PI staining, respectively. As shown in Fig. 4Citation , although Z-VAD.fmk could completely inhibit DNA fragmentation in NK-72 cells and Jurkat T lymphocytes, it failed to prevent loss of plasma membrane integrity in either cell type, a hallmark of necrosis. Therefore, caspases inhibited by Z-VAD.fmk appear responsible for triggering the apoptotic process in cells treated with TPEN. Furthermore, modulation of caspase activity is a critical determinant of the mode of cell death.



View larger version (28K):
[in this window]
[in a new window]
  		Fig. 4. TPEN induces necrosis in the NK-72 cell line and Jurkat T lymphocytes when the apoptotic mode of death is prevented. A, inhibition of TPEN induced apoptosis by Z-VAD.fmk. NK-72 and Jurkat cells were treated with 25 µM TPEN for 24 h in the presence or absence of 50 µM Z-VAD.fmk. Apoptotic DNA fragmentation was determined as described in Fig. 1Citation . X axis, DNA content; Y axis, fluorescence intensity. B, aliquots of the same cells were used to measure the percentage of dead cells using FACS analysis of PI-stained nuclei. X axis, fluorescence intensity; Y axis, cell number.

 
Deficient expression of particular caspases documented in various malignancies may give tumor cells a significant survival advantage only in situations where apoptosis is initiated through death receptors such as CD95 and tumor necrosis factor receptor-1. Nevertheless, death in these tumor cells will invariably proceed when induced by agents triggering mitochondrial changes directly. In contrast, tumor cells overexpressing antiapoptotic proteins such as Bcl-2 and Bcl-x, which act at the level of mitochondria (21) , are protected from both modes of death, apoptosis and necrosis. Additional studies of caspase-dependent and -independent death pathways aimed at understanding the role of specific participants of these pathways in life and death decisions may provide new targets for antitumor drug development and may help predict the efficacy of new therapeutic agents more accurately.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by USPHS Grant CA56937 and the American Foundation for Urological Disease. Back

2 These authors contributed equally to this work. Back

3 To whom requests for reprints should be addressed, at The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195. Phone: (216) 444-5186; Fax: (216) 444-9329. Back

4 The abbreviations used are: TPEN, N,N,N'N'-tetrakis (2-pyridylmethyl) ethylenediamine; FACS, fluorescence-activated cell sorter; RCC, renal cell carcinoma; PI, propidium iodide; TUNEL, terminal deoxynucleotidyl transferase-mediated nick end labeling. Back

5 R. G. Uzzo, V. Kolenko, C. J. Froelich, A. C. Novick, R. M. Bukowski, and J. Finke. Granzyme B induces cell death in CD95 resistant human renal cell carcinoma, manuscript in preparation. Back

6 V. Kolenko, R. G. Uzzo, R. M. Bukowski, and J. Finke. Chelation of intracellular zinc induces CD95-independent apoptosis in T lymphocytes via alterations in the mitochondrial permeability transition, manuscript in preparation. Back

Received 3/ 3/99. Accepted 5/ 3/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Hannun Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood, 89: 1845-1853, 1997.[Free Full Text]
  2. Sayers T. J., Brooks A. D., Lee J. K., Fenton R. G., Komschlies K. L., Wigginton J. M., Winkler-Pickett R., Wiltrout R. H. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J. Immunol., 161: 3957-3965, 1998.[Abstract/Free Full Text]
  3. Earnshaw W. C. Nuclear changes in apoptosis. Curr. Opin. Cell Biol., 7: 337-343, 1995.[Medline]
  4. Martinez-Lorenzo M. J., Gamen S., Etxeberria J., Lasierra P., Larrad L., Pineiro A., Anel A., Naval J., Alava M. A. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells. Int. J. Cancer, 75: 473-481, 1998.[Medline]
  5. Coustan-Smith E., Kitanaka A., Pui C. H., McNinch L., Evans W. E., Raimondi S. C., Behm F. G., Arico M., Campana D. Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood, 87: 1140-1146, 1996.[Abstract/Free Full Text]
  6. Zamzami N., Susin S. A., Marchetti P., Hirsch T., Gomez-Monterrey I., Castedo M., Kroemer G. Mitochondrial control of nuclear apoptosis. J. Exp. Med., 183: 1533-1544, 1996.[Abstract/Free Full Text]
  7. Green D., Kroemer G. The central executioners of apoptosis: caspases or mitochondria?. Trends Cell Biol., 8: 267-271, 1998.[Medline]
  8. Hirsch T., Marchetti P., Susin S. A., Dallaporta B., Zamzami N., Marzo I., Geuskens M., Kroemer G. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene, 15: 1573-1581, 1997.[Medline]
  9. Ebert T., Bander N. H., Finstad C. L., Ramsawak R. D., Old L. J. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res., 50: 5531-5536, 1990.[Abstract/Free Full Text]
  10. Nicoletti I., Migliorati G., Pagliacci M. C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.[Medline]
  11. Schreiber E., Matthias P., Muller M. M., Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells. Nucleic Acids Res., 17: 6419 1989.[Free Full Text]
  12. Nicholson D. W., Thornberry N. A. Caspases: killer proteases. Trends Biochem. Sci., 22: 299-306, 1997.[Medline]
  13. Salvesen G. S., Dixit V. M. Caspases: intracellular signaling by proteolysis. Cell, 91: 443-446, 1997.[Medline]
  14. Rokhlin O. W., Bishop G. A., Hostager B. S., Waldschmidt T. J., Sidorenko S. P., Pavloff N., Kiefer M. C., Umansky S. R., Glover R. A., Cohen M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res., 57: 1758-1768, 1997.[Abstract/Free Full Text]
  15. Los M., Herr I., Friesen C., Fulda S., Schulze-Osthoff K., Debatin K. M. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood, 90: 3118-3129, 1997.[Abstract/Free Full Text]
  16. Muller M., Strand S., Hug H., Heinemann E. M., Walczak H., Hofmann W. J., Stremmel W., Krammer P. H., Galle P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest., 99: 403-413, 1997.[Medline]
  17. Wolf C. M., Eastman A. The temporal relationship between protein phosphatase, mitochondrial cytochrome c release and caspase activation in apoptosis. Exp. Cell. Res., 247: 505-513, 1999.[Medline]
  18. Green D. R. Apoptotic pathways: the roads to ruin. Cell, 94: 695-698, 1998.[Medline]
  19. Green D. R., Reed J. C. Mitochondria and apoptosis. Science (Washington DC), 281: 1309-1312, 1998.[Abstract/Free Full Text]
  20. Trapani J. A., Jans D. A., Jans P. J., Smyth M. J., Browne K. A., Sutton V. R. Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase dependent, but cell death is caspase-independent. J. Biol. Chem., 273: 27934-27938, 1998.[Abstract/Free Full Text]
  21. Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Washington DC), 275: 1132-1136, 1997.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
Z. T. Schafer, A. B. Parrish, K. M. Wright, S. S. Margolis, J. R. Marks, M. Deshmukh, and S. Kornbluth
Enhanced Sensitivity to Cytochrome c-Induced Apoptosis Mediated by PHAPI in Breast Cancer Cells
Cancer Res., February 15, 2006; 66(4): 2210 - 2218.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
P-Y Fong, W-C Xue, H Y S Ngan, P-M Chiu, K Y K Chan, S W Tsao, and A N Y Cheung
Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study
J. Clin. Pathol., February 1, 2006; 59(2): 179 - 183.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. R. Fantin, M. J. Berardi, H. Babbe, M. V. Michelman, C. M. Manning, and P. Leder
A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells
Cancer Res., August 1, 2005; 65(15): 6891 - 6900.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Mizutani, H. Nakanishi, K. Yamamoto, Y. N. Li, H. Matsubara, K. Mikami, K. Okihara, A. Kawauchi, B. Bonavida, and T. Miki
Downregulation of Smac/DIABLO Expression in Renal Cell Carcinoma and Its Prognostic Significance
J. Clin. Oncol., January 20, 2005; 23(3): 448 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. R. Fantin and P. Leder
F16, a Mitochondriotoxic Compound, Triggers Apoptosis or Necrosis Depending on the Genetic Background of the Target Carcinoma Cell
Cancer Res., January 1, 2004; 64(1): 329 - 336.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Kudo, P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke
Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells
Cancer Res., April 1, 2003; 63(7): 1676 - 1683.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. G. Uzzo, V. Kolenko, C. J. Froelich, C. Tannenbaum, L. Molto, A. C. Novick, N. H. Bander, R. Bukowski, and J. H. Finke
The T Cell Death Knell: Immune-mediated Tumor Death in Renal Cell Carcinoma
Clin. Cancer Res., October 1, 2001; 7(10): 3276 - 3281.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Datta, R. Nambudripad, S. Pal, M. Zhou, H. T. Cohen, and D. Mukhopadhyay
Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer
J. Biol. Chem., June 30, 2000; 275(27): 20700 - 20706.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolenko, V.
Right arrow Articles by Finke, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolenko, V.
Right arrow Articles by Finke, J. H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online